securities fraud

Class action lawsuit filed against $CWH alleging materially false statements on inventory management and consumer demand. Investors have until May 11 to join.

Class action lawsuit filed against $MNDY for allegedly misleading investors about revenue outlook. Investors must act before May 11 lead plaintiff deadline.

Class action lawsuit filed against $GEMI alleging false statements on crypto platform viability and overstated expansion plans. Lead plaintiff deadline May 18, 2026.

Option Care Health stock crashed over 30% after weak Q1 results and slashed full-year guidance due to chronic disease portfolio reset. Law firm investigates potential securities violations.

Class action lawsuit filed against $ATARA alleging securities fraud over false statements regarding manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.

Class action lawsuit filed against $SLNO alleging failure to disclose fluid retention safety concerns in DCCR drug trials, harming investors who bought shares March-November 2025.

Class action lawsuit filed against $FCHL alleging materially false statements and fraudulent social media promotion scheme harming investors during September 2025 window.

Class action lawsuit filed against $VITL alleging false statements about ERP system delays that caused guidance miss. Investors have until May 26, 2026 to join.

Class action filed against $CHOW alleging securities fraud, false statements, and undisclosed market-manipulation scheme involving social media misinformation and fraudulent trading.

SES AI faces securities fraud lawsuit alleging false statements, overstated deals, and customer losses. Stock fell 36.8% to $1.08 after Wolfpack Research report.

Class action lawsuit filed against Regencell Bioscience for alleged false statements and failure to disclose DOJ investigation into trading practices.

Schall Law Firm files securities fraud class action against $ZSPC following December 2024 IPO, citing false disclosures and undisclosed preferred shareholder details.

Schall Law Firm recruits $POET investors for class action lawsuit alleging false statements about tax status and business prospects.

Class action lawsuit filed against Aquestive Therapeutics after company failed to disclose FDA deficiencies blocking Anaphylm approval, triggering 37% stock decline.

Law firm investigates $SES for potential securities fraud after stock plunged 36.8% following disappointing 2026 revenue guidance and prior allegations of customer losses.

POET Technologies faces securities class action over alleged misrepresentations regarding tax status and Marvell Semiconductor agreement during April 2026 purchase window.

Portnoy Law Firm sues Globant on behalf of investors over alleged misrepresentation of Latin American pivot, citing hidden operational failures and workforce cuts.

SES AI stock crashes 37% to $1.08 after securities fraud probe launched over alleged concealment of customer losses and questionable acquisition.

Class action lawsuit filed against $GLOB alleging material misstatements about Latin American demand weakness, frozen wages, and project cancellations. Stock crashed 27.8% in February 2025.

Class action lawsuit filed against $GLOB alleges materially false statements regarding Latin America business challenges. Stock plummeted 27.8% in February 2025 after missed guidance.